Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis.

Authors: Bruno Sangro, Mohamed Bouattour, Joong-Won Park, Dr. Consuelo Diaz, Joseph P. Erinjeri, Gustavo Vasconcelos Alves, Shan-Zhi Gu, Aleksei Manikhas, Hidekatsu Kuroda, Thatthan Suksombooncharoen, Truc Hoi Trung Vo, Vikas S. Ostwal, Melissa A. Eastgate, Gina M. Vaccaro, Rebecca Griffin, Sajid Ali, Kavitha Balaji, Stephen Lam Chan

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.574

Source: Full article

---

Abstract

574